Rigel Pharmaceuticals (RIGL) Competitors $20.13 +2.78 (+16.02%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RIGL vs. INVA, OPK, IRWD, EBS, CDXS, XOMA, VNDA, VSTM, SGMO, and LXRXShould you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Emergent BioSolutions (EBS), Codexis (CDXS), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Sangamo Therapeutics (SGMO), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "biotechnology" industry. Rigel Pharmaceuticals vs. Innoviva OPKO Health Ironwood Pharmaceuticals Emergent BioSolutions Codexis XOMA Vanda Pharmaceuticals Verastem Sangamo Therapeutics Lexicon Pharmaceuticals Rigel Pharmaceuticals (NASDAQ:RIGL) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations. Is RIGL or INVA more profitable? Innoviva has a net margin of 18.31% compared to Rigel Pharmaceuticals' net margin of 2.46%. Innoviva's return on equity of 20.84% beat Rigel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rigel Pharmaceuticals2.46% -14.80% 3.03% Innoviva 18.31%20.84%11.38% Does the MarketBeat Community believe in RIGL or INVA? Rigel Pharmaceuticals received 162 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 68.85% of users gave Rigel Pharmaceuticals an outperform vote while only 57.58% of users gave Innoviva an outperform vote. CompanyUnderperformOutperformRigel PharmaceuticalsOutperform Votes46268.85% Underperform Votes20931.15% InnovivaOutperform Votes30057.58% Underperform Votes22142.42% Do insiders and institutionals hold more shares of RIGL or INVA? 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 9.0% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable valuation and earnings, RIGL or INVA? Innoviva has higher revenue and earnings than Rigel Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRigel Pharmaceuticals$116.88M3.03-$25.09M$0.14143.80Innoviva$310.46M3.75$179.72M$0.6926.93 Does the media refer more to RIGL or INVA? In the previous week, Rigel Pharmaceuticals had 19 more articles in the media than Innoviva. MarketBeat recorded 20 mentions for Rigel Pharmaceuticals and 1 mentions for Innoviva. Innoviva's average media sentiment score of 1.78 beat Rigel Pharmaceuticals' score of 0.58 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate RIGL or INVA? Rigel Pharmaceuticals currently has a consensus price target of $36.20, suggesting a potential upside of 79.83%. Given Rigel Pharmaceuticals' higher probable upside, equities research analysts clearly believe Rigel Pharmaceuticals is more favorable than Innoviva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Innoviva 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, RIGL or INVA? Rigel Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. SummaryInnoviva beats Rigel Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RIGL vs. The Competition Export to ExcelMetricRigel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$286.24M$6.37B$5.23B$8.96BDividend YieldN/A2.94%5.13%4.04%P/E Ratio143.808.3083.3616.84Price / Sales3.03311.691,257.9179.09Price / CashN/A61.4443.8235.97Price / Book-12.276.055.324.79Net Income-$25.09M$154.90M$122.78M$224.99M7 Day Performance23.88%-1.73%-0.20%1.50%1 Month Performance17.93%2.68%3.71%4.68%1 Year Performance50.22%2.76%27.30%20.92% Rigel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RIGLRigel Pharmaceuticals3.9495 of 5 stars$20.13+16.0%$36.20+79.8%+49.1%$286.24M$116.88M143.80160Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageGap UpHigh Trading VolumeINVAInnoviva1.6411 of 5 stars$17.50+1.3%N/A+15.4%$1.10B$352.75M25.36100Positive NewsOPKOPKO Health4.462 of 5 stars$1.53+4.1%$2.75+79.7%+49.1%$1.04B$863.50M-8.053,930Analyst DowngradeInsider TradeNews CoverageIRWDIronwood Pharmaceuticals4.3573 of 5 stars$3.60-9.1%$10.40+188.9%-70.4%$576.10M$378.42M-120.00220Short Interest ↓News CoveragePositive NewsGap DownEBSEmergent BioSolutions4.2377 of 5 stars$9.36-5.3%$14.33+53.1%+415.9%$507.16M$1.09B-2.281,600Analyst UpgradeGap DownCDXSCodexis3.8752 of 5 stars$4.50+2.5%$8.33+85.2%+86.6%$366.20M$64.45M-5.17250Short Interest ↑News CoverageXOMAXOMA4.1696 of 5 stars$25.52+1.4%$81.50+219.4%+38.4%$300.70M$9.71M-7.3310Analyst UpgradeVNDAVanda Pharmaceuticals3.8895 of 5 stars$4.50-2.2%$15.50+244.4%+16.0%$262.39M$190.86M-16.07290VSTMVerastem2.7566 of 5 stars$5.33-7.0%$13.38+150.9%-52.0%$237.22M$10M-1.6750SGMOSangamo Therapeutics2.7783 of 5 stars$1.06-9.0%$5.50+418.9%+145.2%$221.17M$52.29M-1.41480Gap DownLXRXLexicon Pharmaceuticals1.746 of 5 stars$0.68-11.7%$6.00+787.2%-49.6%$166.53M$5.23M-0.90140 Related Companies and Tools Related Companies Innoviva Alternatives OPKO Health Alternatives Ironwood Pharmaceuticals Alternatives Emergent BioSolutions Alternatives Codexis Alternatives XOMA Alternatives Vanda Pharmaceuticals Alternatives Verastem Alternatives Sangamo Therapeutics Alternatives Lexicon Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RIGL) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.